Halozyme Therapeutics Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Halozyme Therapeutics Inc 's ROA in the third quarter of 2026?
Halozyme Therapeutics Inc achieved a return on average assets (ROA) of 17.22 % in its third quarter of 2026, this is above HALO's average return on assets of -10.01%.
Halozyme Therapeutics Inc s assets during the 12 months ending in the third quarter of 2026 are valued at $2 billion

ROA has improved compared to 16.61% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 56 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 363, from total ROA ranking in the second quarter of 2026 at 433.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	60.47 %	28.95 %	24.89 %	28.09 %	6.26 %
Y / Y Net Income Change	40.99 %	39.21 %	27.06 %	-	27.89 %
Net Income (TTM) in million	485	414	349	317	595
Return On Assets (TTM)	17.22 %	16.61 %	14.87 %	14.32 %	28.72 %
HALO's Total Ranking	# 363	# 433	# 158	# 155	# 184
Total Assets (TTM) in million	3,479	2,577	2,675	2,542	2,168
Seq. Total Assets Change	34.99 %	-3.65 %	5.21 %	17.27 %	8.47 %
Seq. Net Income Change	7.45 %	53.23 %	-	-	6.09 %

HALO's 5 Years Annual ROA >> Back to HALO Management Effectiveness >> Compare HALO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 12
Sector	# 57
Overall	# 280

Return On Assets Statistics
High	Average	Low
43.55 %	-10.01 %	-76.55 %
(Sep 30 2021)		(Dec 31 2013)

Financial Statements
Halozyme Therapeutics Inc 's Assets	$ 3,479 million	HALO's Balance sheet
Halozyme Therapeutics Inc 's Income	$ 247 million	Quarterly HALO's Income Statement
HALO's Income by Division		See HALO's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	27.35 %	15.53 %	-5.4 %	66.35 %	92.94 %
Total Assets in million	2,528	1,985	1,718	1,816	1,092
Y / Y Net Income Change	-28.64 %	57.71 %	39.31 %	-49.81 %	211.97 %
Net Income in million	317	444	282	202	403
Annual Return On Assets	12.54 %	22.37 %	16.39 %	11.13 %	36.89 %

HALO's 5 Years Annual ROA >> Back to HALO Management Effectiveness >> Compare HALO ROA to its Competitors

Comment on HALO's ROA in the fiscal year ending 2025

In the fiscal year 2025 Halozyme Therapeutics Inc 's ROA decreased compared to previous year to 12.54 %, due to deterioration of net income -28.64 % to $316.89 million, from $444.09 million a year ago, as HALO's assets were $2,527.92 million.

More Return On Assets Ratios
HALO's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
HALO's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for HALO's Competitors
Subscribers only: Roa for Halozyme Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for HALO's Customers

You may also want to know
HALO's Roi	HALO's Inventory Turnover Ratio	HALO's Growth Rates	HALO's Dividend Comparisons
	HALO's Profitability Ratios	HALO's Asset Turnover Ratio	HALO's Dividend Growth
HALO's Roe	HALO's Valuation Ratios	HALO's Financial Strength Ratios	HALO's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Alnylam Pharmaceuticals Inc	46.08 %
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %

Date modified: 2026-11-09T06:45:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.